**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 66-year-old woman developed QT prolongation with a notched broad T-wave during off-label treatment with azithromycin and hydroxychloroquine for coronavirus disease-2019 (COVID-19).

The woman with a significant medical history of rheumatoid arthritis, asthma and pulmonary fibrosis had been receiving methotrexate and unspecified steroids. On 16 March 2020, she presented with cough and fever after treatment with doxycycline followed by levofloxacin for sinus as well as upper respiratory tract symptoms. Investigations led to a diagnosis of COVID-19. She developed respiratory failure, and was intubated. She received adrenergic support with norepinephrine. On 18 March 2020, she started receiving off-label treatment with IV azithromycin. On 21 March 2020, off-label hydroxychloroquine was added to her therapy \[*dosages not stated; not all routes stated*\]; however, she exhibited QTc of 620ms with a notched broad T-wave. She was found to have developed QT prolongation secondary to hydroxychloroquine and azithromycin.

Therefore, the woman\'s hydroxychloroquine treatment was discontinued following one dose. Ventricular ectopy was not present. Her serum magnesium and potassium levels were 2.9 mg/dL and 4.4mM, respectively. She was treated with lidocaine followed by a repeat 12-lead ECG, which demonstrated a shortening of the QTc to 550ms.

The woman received hydroxychloroquine again along with lidocaine. She was able to complete the hydroxychloroquine course with no arrhythmic event. On 25 March 2020, she died of progressive metabolic acidosis as well as multi-organ system failure, which were due to her underlying COVID-19.
